22nd Century (XXII) Stock
Plant genetics company developing reduced nicotine tobacco. Here's the price, business snapshot, and what's worth knowing about 22nd Century in October 2026.
22nd Century Group, Inc. (XXII) is a micro-cap company focused on plant genetics and nicotine management. Its principal work has involved breeding and developing tobacco with reduced nicotine levels using proprietary biological techniques, and exploring commercial routes such as licensing and product partnerships. For investors this stock is highly speculative: the company’s market capitalisation is tiny and liquidity can be limited, so price swings and volatility are common. Potential upside can come from licensing deals, regulatory developments that favour reduced-nicotine products, or successful commercialisation of its technologies. Equally, the business faces regulatory scrutiny, shifting consumer trends, competitive pressures and the risk of fundraising dilution. This summary is for general educational purposes only and is not personalised investment advice. Consider suitability carefully: this stock is generally appropriate only for investors comfortable with high-risk, small-cap opportunities and the possibility of losing capital.
22nd Century (XXII) Stock Forecast
Analyst price target, next 12 months
$9.00
+884.7% vs today's $0.91
Price range over the last 12 months
Close to its 12-month low
Analysts covering 22nd Century have a consensus 12-month target of $9.00, above the current price of $0.91.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 12 Jun 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying 22nd Century Group's stock with a target price of $9, indicating potential growth.
Financial Health
22nd Century Group shows modest revenue and cash flow, but its financial position needs improvement.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Nicotine‑reduction science
The company’s IP centres on lowering nicotine through plant genetics — a niche scientific angle that could drive licensing income, though commercial success is uncertain.
Catalysts to watch
Look for licensing agreements, regulatory decisions, or commercial partnerships — any of which could move the stock, but outcomes are speculative and may not materialise.
Regulatory landscape
Policy on nicotine and tobacco products is a key influence; regulation can create opportunities or constraints, so regulatory shifts should be monitored closely.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.